Q-omics provides the consensus-scored SLC35E2B profile across patient tissues and cancer cell-line models. SLC35E2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SLC35E2B is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, SLC35E2B RNA expression shows 20,424 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, LIHC, and DLBC as cancer lineages where SLC35E2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35E2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35E2B survival associations across molecular data types. SLC35E2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35E2B RNA expression–survival associations across cancer types. High SLC35E2B expression shows favorable associations in HNSC, BRCA, SCLC, MESO, UCS and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SLC35E2B RNA expression.
This table summarizes SLC35E2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC35E2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35E2B shows lower tumor expression in KICH and COAD and higher tumor expression in LIHC, CHOL, KIRP and PRAD. The LIHC box plot shows higher SLC35E2B RNA expression in tumor versus normal tissue (log2 FC = +0.990, t-test p < 0.001).
This table shows molecular features associated with SLC35E2B in patient tissues and cancer cell lines. In patient samples, SLC35E2B shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35E2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
